About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

HK-001

Company: Everfront Biotech Co., Ltd.
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 12, 2026

Trial details

Active, not recruiting NCT NCT03651349

To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers

Not yet reported Everfront Biotech Co., Ltd. 56 participants Est. completion 2028-06-30 1 site Stand-alone

Other conditions: Amyotrophic Lateral Sclerosis
View official trial listing →
Not yet recruiting NCT NCT07349693

Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma

Not yet reported, Not yet reported Everfront Biotech Co., Ltd. 175 participants Est. completion 2029-12-31 1 site

Other conditions: Recurrent Glioblastoma, IDH-Wildtype
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT03651349

Also known as: HK-001, (Z)-n-butylidenephthalide [(Z)-BP]

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.